Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The eukaryotic 28S ribosomal RNA sarcin–ricin loop (SRL) is a nearly universal and highly conserved 12-nucleotide RNA motif located in the large (60S) ribosomal subunit [PubMed: 8677602]. It serves as a critical docking site for translation elongation factors, specifically eEF-1 and eEF-2, and is essential for triggering the GTP hydrolysis required for tRNA translocation and ribosome movement along mRNA [PubMed: 31133953]. The SRL is famously the target of potent toxins known as Ribosome-Inactivating Proteins (RIPs), such as ricin from castor beans and Shiga toxins from bacteria [PubMed: 17113994]. These toxins act as N-glycosidases that specifically depurinate a single adenine residue (A4324 in humans) within the loop, while ribotoxins like alpha-sarcin cleave the phosphodiester backbone [PubMed: 20660480]. These modifications disrupt the interaction between the ribosome and elongation factors, leading to a complete and irreversible halt in protein synthesis and subsequent cell death [PubMed: 17113994]. Consequently, the SRL is a focal point in toxicology and is exploited in biotechnology to create targeted immunotoxins for cancer treatment [PubMed: 16648870].
Ribosome-inactivating proteins (RIPs) target the SRL to either depurinate a specific adenine residue (N-glycosidase activity) or cleave the RNA backbone (ribonuclease activity), which irreversibly inhibits protein synthesis by preventing elongation factor binding [PubMed: 8677602, 17113994].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic 28S ribosomal RNA sarcin–ricin loop (SRL).